Abstract
The anti-idiotype monoclonal antibody breast cancer vaccine 11D10 (TriAb®) was administered before and after autologous stem cell transplantation (ASCT) in 45 patients with metastatic breast cancer whose disease was responsive to conventional chemotherapy. Evidence of a positive anti-anti-idiotype antibody (Ab3) humoral response was noted at a median of 1.75 months post-ASCT (range, before ASCT-6 months) with this strategy. Maximal Ab3 levels and idiotype-specific T-cell proliferative responses were observed at a median of 3 and 4 months, respectively, after ASCT. The achievement of rapid immune responses after ASCT, during a known period of decreased immunoresponsiveness, opens the possibility of an additional antitumor effect at a time when the tumor burden is relatively small. Moreover, in this interim analysis, patients with the most vigorous humoral and cellular immune responses had a significant improvement in progression-free survival. Further follow-up and evaluation of this approach is warranted.
Original language | English |
---|---|
Pages (from-to) | 52-58 |
Number of pages | 7 |
Journal | Clinical breast cancer |
Volume | 2 |
Issue number | 1 |
DOIs | |
State | Published - Apr 2001 |
Keywords
- Autotransplantation
- Human milk fat globule
- T-cell proliferative response
- TriAb breast cancer vaccine